392 related articles for article (PubMed ID: 24493592)
1. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands.
Geyer R; Kaske M; Baumeister P; Buschauer A
Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592
[TBL] [Abstract][Full Text] [Related]
2. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
[TBL] [Abstract][Full Text] [Related]
3. Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
Geyer R; Nordemann U; Strasser A; Wittmann HJ; Buschauer A
J Med Chem; 2016 Apr; 59(7):3452-70. PubMed ID: 27007611
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.
Igel P; Geyer R; Strasser A; Dove S; Seifert R; Buschauer A
J Med Chem; 2009 Oct; 52(20):6297-313. PubMed ID: 19791743
[TBL] [Abstract][Full Text] [Related]
6. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
[TBL] [Abstract][Full Text] [Related]
7. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
8. Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands.
Kottke T; Sander K; Weizel L; Schneider EH; Seifert R; Stark H
Eur J Pharmacol; 2011 Mar; 654(3):200-8. PubMed ID: 21237145
[TBL] [Abstract][Full Text] [Related]
9. Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates.
Łazewska D; Wiecek M; Ligneau X; Kottke T; Weizel L; Seifert R; Schunack W; Stark H; Kieć-Kononowicz K
Bioorg Med Chem Lett; 2009 Dec; 19(23):6682-5. PubMed ID: 19846299
[TBL] [Abstract][Full Text] [Related]
10. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
[TBL] [Abstract][Full Text] [Related]
11. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
Hashimoto T; Harusawa S; Araki L; Zuiderveld OP; Smit MJ; Imazu T; Takashima S; Yamamoto Y; Sakamoto Y; Kurihara T; Leurs R; Bakker RA; Yamatodani A
J Med Chem; 2003 Jul; 46(14):3162-5. PubMed ID: 12825954
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
13. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
[TBL] [Abstract][Full Text] [Related]
14. Tritium-labeled N(1)-[3-(1H-imidazol-4-yl)propyl]-N(2)-propionylguanidine ([(3)H]UR-PI294), a high-affinity histamine H(3) and H(4) receptor radioligand.
Igel P; Schnell D; Bernhardt G; Seifert R; Buschauer A
ChemMedChem; 2009 Feb; 4(2):225-31. PubMed ID: 19101971
[TBL] [Abstract][Full Text] [Related]
15. Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.
Kitbunnadaj R; Zuiderveld OP; Christophe B; Hulscher S; Menge WM; Gelens E; Snip E; Bakker RA; Celanire S; Gillard M; Talaga P; Timmerman H; Leurs R
J Med Chem; 2004 May; 47(10):2414-7. PubMed ID: 15115383
[TBL] [Abstract][Full Text] [Related]
16. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
[TBL] [Abstract][Full Text] [Related]
17. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
[TBL] [Abstract][Full Text] [Related]
18. Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.
Wijtmans M; de Graaf C; de Kloe G; Istyastono EP; Smit J; Lim H; Boonnak R; Nijmeijer S; Smits RA; Jongejan A; Zuiderveld O; de Esch IJ; Leurs R
J Med Chem; 2011 Mar; 54(6):1693-703. PubMed ID: 21348462
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity.
Kuder KJ; Stachnik M; Schunack W; Szymańska E; Kieć-Kononowicz K
Med Chem; 2014; 10(6):588-99. PubMed ID: 24047214
[TBL] [Abstract][Full Text] [Related]
20. Histamine H3 and H4 receptors as novel drug targets.
Tiligada E; Zampeli E; Sander K; Stark H
Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]